Secondary prevention of ischaemic stroke: Antiplatelet drugs and heparin

被引:0
|
作者
Diener, HC [1 ]
机构
[1] Univ Essen Gesamthsch, Neurol Klin, D-45122 Essen, Germany
关键词
D O I
10.1055/s-2007-1017694
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Treatment with antiplatelet drugs reduces stroke risk by 20 to 30% in patients with TIA or previous stroke. All doses of aspirin are equally effective. Lower doses should therefore be preferred. Gastrointestinal side effects of aspirin increase with dose, whereas severe bleeding complications do not. The combination of two antiplatelet drugs (aspirin plus dipyridamole) is more effective than aspirin alone. Ticlopidine and clopidogrel are two other new antiplatelet drugs for the prevention of stroke, myocardial infarction and Vascular death. Early secondary prevention with aspirin is only marginaly beneficial. Heparin reduces the number of early stroke recurrences while at the same time increasing the risk of cerebral haemorrhage.
引用
收藏
页码:227 / 233
页数:9
相关论文
共 50 条
  • [41] Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke
    Warden, Bruce A.
    Willman, Alana M.
    Williams, Craig D.
    NATURE REVIEWS NEUROLOGY, 2012, 8 (04) : 223 - 235
  • [42] Drug treatments in the secondary prevention of ischaemic stroke
    Schulz, Ursula G.
    MATURITAS, 2013, 76 (03) : 267 - 271
  • [43] STROKE Secondary stroke prevention-personalized antiplatelet therapy
    Tanne, David
    NATURE REVIEWS NEUROLOGY, 2012, 8 (10) : 536 - 537
  • [44] Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis
    Niu, Peng-Peng
    Guo, Zhen-Ni
    Jin, Hang
    Xing, Ying-Qi
    Yang, Yi
    BMJ OPEN, 2016, 6 (03):
  • [45] Use of antiplatelet drugs in stroke prevention: time for a rethink?
    Loke, Yoon K.
    White, James R.
    Bettencourt-Silva, Joao H.
    Potter, John F.
    Myint, Phyo K.
    POSTGRADUATE MEDICAL JOURNAL, 2013, 89 (1052) : 309 - 310
  • [46] Antiplatelet resistance in ischaemic stroke
    Mohan, R. S.
    AUSTRALASIAN JOURNAL ON AGEING, 2019, 38 : 66 - 66
  • [47] Selecting an Optimal Antiplatelet Agent for Secondary Stroke Prevention
    Albright, Karen C.
    Howard, Virginia J.
    Howard, George
    NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (02) : E121 - E128
  • [48] Antiplatelet Agents' Effectiveness for Secondary Prevention of Ischemic Stroke
    Kim, Mi-Sook
    Kim, Ye-Jee
    Seong, Jong-Mi
    Choi, Nam-Kyong
    Park, Byung-Joo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S218 - S218
  • [49] TICLOPIDINE - A NEW ANTIPLATELET AGENT FOR THE SECONDARY PREVENTION OF STROKE
    MURRAY, JC
    KELLY, MA
    GORELICK, PB
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) : 23 - 31
  • [50] Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention
    Srivastava, Padma
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2010, 13 (01) : 6 - 13